Melbourne, Australia; 16 October 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the poster that showcases the results from a study of DEP^® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model. These results were announced by Starpharma in July 2023¹.

The poster was presented over the weekend in Boston, US, at the International Conference on Molecular Targets and Cancer Therapeutics, co-hosted by the American Association of Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) from 11 to 15 October 2023.

Starpharma’s DEP^® HER2-zirconium is a radiodiagnostic product that belongs to the rapidly growing radiotheranostic market. DEP^® HER2-zirconium is designed to specifically diagnose, stage, and monitor HER2+ cancers with greater sensitivity, meaning that patients suffering from these cancers could be diagnosed earlier, more accurately, and monitored more closely during cancer treatment.

Starpharma CEO, Dr Jackie Fairley, said: “We are pleased to be presenting results on DEP^® HER2-zirconium, our HER2-targeted radiodiagnostic candidate at this AACR international conference and to see the data on this product generate such positive interest. Radiotheranostics are an exciting new area for the application of our DEP^® platform, which represents a significant global market opportunity that is expected to be US$4.2 billion by 2030². This poster is one of three which Starpharma presented in Boston.”

The poster is appended.

View or download the ASX Announcement, here.

¹ ASX Announcement dated 21 July 2023: DEP^® HER2-radiodiagnostic shows imaging benefits.
² https://www.giiresearch.com/report/dmin1316304-global-theranostics-market.html